PriceTargets.com logo

Nuvation Bio - NUVB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $9.67
  • Forecasted Upside: 16.12%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$8.33 As of 12/4/2025 04:59 PM ET
▼ -0.045 (-0.54%)

This chart shows the closing price for NUVB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nuvation Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVB

Analyst Price Target is $9.67
▲ +16.12% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $9.67, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 16.12% upside from the last price of $8.33.

This chart shows the closing price for NUVB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in Nuvation Bio. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
11/24/2025Truist FinancialSet Target$11.00
11/24/2025Truist FinancialInitiated CoverageBuy$11.00
11/20/2025JMP SecuritiesSet Target$10.00
11/20/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00
11/19/2025B. RileyInitiated CoverageBuy$12.00
11/18/2025B. RileyInitiated CoverageBuy$12.00
11/4/2025JMP SecuritiesSet Target$8.00
11/4/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
11/4/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$7.00 ➝ $8.00
11/4/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00
10/13/2025WedbushReiterated RatingOutperform ➝ Outperform$6.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$10.00
9/30/2025Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$10.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/19/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00
9/8/2025WedbushReiterated RatingOutperform ➝ Outperform$6.00
8/8/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$6.00 ➝ $7.00
6/25/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$6.00
6/17/2025Royal Bank Of CanadaUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.00
6/11/2025WedbushReiterated RatingOutperform ➝ Outperform$5.00
6/2/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$6.00
5/15/2025WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
4/23/2025CitigroupInitiated CoverageOutperform
4/23/2025Citizens JmpInitiated CoverageMkt Outperform$6.00
4/23/2025JMP SecuritiesInitiated CoverageMarket Outperform$6.00
3/27/2025WedbushReiterated RatingOutperform$5.00
3/12/2025Jones TradingInitiated CoverageBuy$10.00
3/11/2025Jones TradingUpgradeStrong-Buy
3/10/2025HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $10.00
3/3/2025WedbushReiterated RatingOutperform$5.00
1/23/2025HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $11.00
1/7/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$6.00 ➝ $10.00
1/6/2025WedbushReiterated RatingOutperform$5.00
1/6/2025HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
12/23/2024WedbushReiterated RatingOutperform$5.00
11/7/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$5.00 ➝ $6.00
11/7/2024WedbushReiterated RatingOutperform$5.00
10/22/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
9/16/2024HC WainwrightLower TargetBuy ➝ Buy$8.00 ➝ $7.00
9/11/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
8/22/2024WedbushReiterated RatingOutperform$5.00
8/6/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
8/5/2024WedbushReiterated RatingOutperform$5.00
7/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/24/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
5/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$8.00
5/15/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00
4/17/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$4.00 ➝ $5.00
3/28/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $8.00
3/27/2024Jefferies Financial GroupUpgradeHold ➝ Buy$1.40 ➝ $10.00
3/26/2024BTIG ResearchUpgradeNeutral ➝ Buy$5.00
3/7/2024HC WainwrightBoost TargetBuy ➝ Buy$4.50 ➝ $5.00
3/1/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00
11/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$4.50
8/21/2023HC WainwrightReiterated RatingBuy ➝ Buy$4.50
8/4/2023WedbushReiterated RatingOutperform$5.00
3/24/2023HC WainwrightReiterated RatingBuy$4.50
3/16/2023Royal Bank Of CanadaReiterated RatingOutperform$6.00
3/16/2023WedbushReiterated RatingOutperform$5.00
1/6/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$5.00 ➝ $2.00
8/22/2022HC WainwrightLower TargetBuy$14.00 ➝ $4.50
8/2/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$8.00 ➝ $2.50
8/2/2022BTIG ResearchDowngradeBuy ➝ Neutral
8/1/2022WedbushLower TargetOutperform$17.00 ➝ $5.00
5/10/2022WedbushLower TargetOutperform$23.00 ➝ $17.00
5/4/2022HC WainwrightInitiated CoverageBuy$14.00
3/22/2022BMO Capital MarketsLower TargetOutperform$17.00 ➝ $12.00
3/1/2022WedbushReiterated RatingOutperform$23.00
4/6/2021Royal Bank Of CanadaInitiated CoverageOutperform$15.00
3/15/2021BTIG ResearchReiterated RatingBuy$16.00
3/8/2021Jefferies Financial GroupInitiated CoverageBuy$20.00
3/8/2021CowenInitiated CoverageOutperform
3/8/2021WedbushInitiated CoverageOutperform$20.00
3/8/2021BTIG ResearchInitiated CoverageBuy$16.00
3/8/2021BMO Capital MarketsInitiated CoverageOutperform$16.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 11 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 10 very positive mentions
  • 13 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 6 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 8 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/5/2025
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 20 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 20 very positive mentions
  • 31 positive mentions
  • 1 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Nuvation Bio logo
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Read More

Today's Range

Now: $8.33
Low: $8.11
High: $8.56

50 Day Range

MA: $5.12
Low: $3.20
High: $8.35

52 Week Range

Now: $8.33
Low: $1.54
High: $8.56

Volume

7,241,905 shs

Average Volume

9,797,363 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvation Bio?

The following Wall Street research analysts have issued stock ratings on Nuvation Bio in the last twelve months: B. Riley, Citigroup Inc., Citizens Jmp, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Jones Trading, Royal Bank Of Canada, Truist Financial Corporation, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for NUVB.

What is the current price target for Nuvation Bio?

0 Wall Street analysts have set twelve-month price targets for Nuvation Bio in the last year. Their average twelve-month price target is $9.67, suggesting a possible upside of 16.1%. B. Riley has the highest price target set, predicting NUVB will reach $12.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $6.00 for Nuvation Bio in the next year.
View the latest price targets for NUVB.

What is the current consensus analyst rating for Nuvation Bio?

Nuvation Bio currently has 1 sell rating, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NUVB.

What other companies compete with Nuvation Bio?

Other companies that are similar to Nuvation Bio include Avidity Biosciences, Qiagen, Moderna, Abivax and Cytokinetics. Learn More about companies similar to Nuvation Bio.

How do I contact Nuvation Bio's investor relations team?

Nuvation Bio's physical mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The company's listed phone number is 332-208-6102 and its investor relations email address is [email protected]. The official website for Nuvation Bio is www.nuvationbio.com. Learn More about contacing Nuvation Bio investor relations.